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OBJECTIVES: To describe health resource utilization (HRU) patterns among 
patients with systemic lupus erythematosus (SLE) prescribed belimumab in U.S 
clinical practice settings. METHODS: OBSErve (BLM117295) is a multi-center 
retrospective medical chart review study. Ninety-two rheumatologists from non-
academic-centers in the U.S randomly identified adult SLE patients in their 
practice who had received at least 8 infusions of belimumab (10mg/kg) as part of 
usual-care. Index-date is the date of the first belimumab infusion. Physicians 
assessed the following data corresponding to the 6 months pre- and post-index 
periods: patient demographics, comorbidities, SLE disease characteristics/ 
outcomes, and HRU (hospitalization/ER/office-visits, ancillary care 
(physical/occupational therapy/home health), medications). Patterns of HRU in 
the 6 months pre- and post-index period are reported from univariate 
(comparative) analysis and two-sided tests of significance (p<0.05). RESULTS: 
Physicians abstracted 501 eligible patient-charts (mean age:41.3yrs, female:89%, 
Caucasian:53%, black/African-American:24%, Hispanic:18%, other:5%; 
Medicare:13%, Medicaid:14%, commercial-insurance:62%; diagnosed with SLE <5 
yrs ago:56%); 3%/77%/20% had mild/moderate/severe disease at baseline, per 
physician judgment. In the pre-index period, concomitant medications included 
oral steroids(78%), antimalarials(70%), immunosuppressants(61%) and 
NSAIDs(16%). In post-index period, among those on oral steroids, 9% 
discontinued steroids and 77% decreased the dose. Percentage of patients with 
>1 hospitalization (pre-index:5%;post-index:2%;p=0.03), >1 ER visits (pre-
index:15%;post-index:6%;p=0.001), >1 unscheduled treating physician visits (pre-
index:52%;post-index:30%;p<0.001), and those receiving any ancillary care (pre-
index:15%;post-index:6%;p=0.001) decreased from pre-index to post-index 
period. The mean number of hospitalizations (pre-index:0.6;post-
index:0.2;p=0.02), ER visits (pre-index:0.2;post-index:0.07;p<0.001), unscheduled 
visits to treating physician (pre-index:1.0;post-index:0.5;p<0.001) and visits to 
other specialty physicians (pre-index:2.0;post-index:1.4;p=0.001) also decreased 
from pre-index to post-index period. CONCLUSIONS: Resource utilization 
decreased in a sample of belimumab treated patients in the first 6-months, in 
comparison to the pre-index period. Association of these observed HRU patterns 
with clinical outcomes and the implications of these observed HRU patterns for 
payers warrants further study.  
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OBJECTIVES: To estimate the economic burden associated with SLE, stratified by 
flare severity in a commercially-insured population in the United States. 
METHODS: In this retrospective, observational study, commercially insured 
adults aged 18-64 years with at least one SLE-related inpatient or emergency 
room (ER) claim or at least two SLE-related outpatient visits at least 30 days apart 
with a rheumatologist between July 1/2004 and December 31, 2008, were 
identified in the MarketScan Commercial Claims and Encounters database. Non-
SLE controls were matched (1:1) to SLE cases on age group, gender, region, and 
index year using propensity scores. Mild, moderate, and severe flares were 
identified in the follow-up period using a claims-based algorithm. A log 
transformed linear regression model was applied to estimate the incremental 
annual economic burden associated with SLE flares by severity. RESULTS: A total 
of 13,460 SLE cases were matched to non-SLE controls. During the variable length 
follow-up period of at least 12 months in duration, SLE cases had a higher rate of 
hospitalization (49.7% vs. 27.7%; p<0.001) and ER visits (66.7% vs. 43.7%, p<0.001) 
compared to non-SLE controls. Among SLE cases with no flares (11.9%), 
mild/moderate (65.9%) and severe flares (22.2%), annualized all-cause direct 
medical costs were $14,945, $21,606 and $64,578 respectively. Multivariate-
adjusted incremental annualized direct medical costs for SLE cases with no 
flares, mild/moderate, and severe flares were $441, $3,606 (p<0.05) and $18,953 
(p<0.05), respectively. CONCLUSIONS: The direct medical costs of patients with 
SLE were significantly higher than controls, with costs increasing substantially 
as the severity of flares increase. Further research examining outcomes 
associated with interventions in patients with SLE may help identify potential 
improvements in patient care and outcomes (including reduction in severe SLE 
flares), while reducing the economic burden of SLE to employers and payers.  
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OBJECTIVES: Treating the approximately 100,000 patients in the United States 
today with sickle cell disease (SCD) can be costly. Identifying the main cost 
drivers of SCD is essential to developing appropriate interventions and 
improving patient outcomes. Real-world insights into the main cost drivers of 
SCD were gathered from the perspective of payers and physicians actively 
treating patients. METHODS: A systematic literature review was conducted on 
resource use and cost drivers associated with SCD, guiding our questionnaire 
development. Three physicians from academic and private practice and nine 
payers (medical, pharmacy or case management directors of large regional or 
national plans with commercial, Medicaid and/or managed Medicaid patients) 
were interviewed about their SCD patient management, resource utilization, and 
cost drivers experiences. RESULTS: Evidence from the published literature 
suggests that a small number of patients account for the majority of resource 
utilization and costs. Studies assessing resource utilization by SCD patients 
reported that 25% of patients accounted for 75% (Medicaid) and 83% (privately 
insured) of costs, and nearly 80% of total inpatient days. Physicians and payers 
indicated that about 10-30% of patients are responsible for the majority of costs. 
Payers also revealed that SCD patients can have “catastrophic” costs, and rank 
among the plan’s top 20 most costly patients. Payers and physicians all reported 
that SCD patients faced barriers to accessing primary care, leading to 
hospitalization and emergency department overuse. Barriers included low 
Medicaid reimbursement rates, lack of transportation, and low health care 
literacy. CONCLUSIONS: Results from this systematic literature review and 
interviews with physicians and payers identify barriers in access to care as a key 
driver for hospitalization and emergency department overuse by SCD patients. 
This suggests that effectively designed disease management programs can help 
patients avoid acute care utilization, delivering better patient care with lower 
costs.  
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OBJECTIVES: To describe the relationship between resource utilisation, inhibitor 
status, treatment regimen and bleed frequency in the HERO Study. METHODS:  
A post-hoc descriptive analysis of adult people with haemophilia (PWH)  
and children with haemophilia (CWH) aged <18 years, with (WI) and without 
inhibitors (WOI), from 8 countries with home treatment 
(AR/CN/DE/FR/IT/SP/UK/US) are presented. RESULTS: Most PWH (431 WOI, 84 WI) 
and CWH (411 WOI, 42 WI) were without inhibitors. Use of on-demand and 
prophylaxis treatment was evenly distributed among PWH (180 on-demand, 203 
prophylaxis); most CWH were on prophylaxis (87 on-demand, 335 prophylaxis). 
Mean/median bleeds per year were higher in PWH WOI on prophylaxis (14.9/5) 
than on-demand (10.3/2), but lower in WI on prophylaxis (5.6/2) than on-demand 
(15.6/7). Higher-risk activities were reported more for PWH on prophylaxis (15% 
vs. 8%) and with decreasing annual bleed rates (15%-9%). Mean/median annual 
bleeds were higher in CWH WOI on on-demand (7.5/3) than prophylaxis (5.2/3) 
and in WI on prophylaxis (12.1/8) than on-demand (9.2/6). Mean annual 
haemophilia treatment centre (HTC) visits were slightly higher on prophylaxis 
for PWH (prophylaxis 4.5, on-demand 3.7) and CWH (prophylaxis 5.6, on-demand 
4.8). For CWH, median HTC visits increased with increasing bleed frequency (2-
5/year). Nurse involvement in haemophilia management was more frequently 
reported by PWH on prophylaxis (57%) than on-demand (45%). Nurse (37%-57%), 
social worker (9%-32%), and physiotherapist (20%-37%) involvement increased 
with bleed frequency in PWH. CWH WI reported more nurse involvement on 
prophylaxis (71%) than on-demand (57%) but less social worker involvement (8% 
vs. 29%); physiotherapists were more frequently involved for CWH WOI on 
prophylaxis (34%, on-demand 23%). CONCLUSIONS: HTC utilisation was higher 
for PWH/CWH on prophylaxis; for CWH, bleed frequency increased utilisation. 
Involvement of physiotherapy and social work was less than expected for 
PWH/CWH, but could positively impact bleed rate; and, overall utilization 
deserves further study.  
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OBJECTIVES: To describe the associations between resource utilisation and 
negative experiences (NEs) with employment, relationships and intimacy in the 
HERO Study. METHODS: A post-hoc descriptive analysis of adult people with 
haemophilia (PWH) and parents of affected children from 8 countries 
(AR/CN/DE/FR/IT/SP/UK/US). RESULTS: Of 515 PWH, 77% reported NEs with work, 
32% relationships (52% intimacy) or 26% telling friends about their haemophilia. 
Of 453 parents, 61% reported NEs with work, 41% telling friends; 77% reported 
impact on unaffected siblings. PWH reporting work-related NEs were less often 
employed (59% vs 80%) and more frequently sought HTC advice on employment 
(32% vs 25%), but fewer with NEs described this advice as very helpful. Parents 
with/without NEs were equally employed. More PWH reporting relationship NEs 
reported NEs with intimacy (30% vs 12%) and friends (39% vs 27%). More PWH 
reporting NEs telling friends reported NEs with relationships (33% vs 22%) and 
intimacy (32% vs 18%). PWH reporting impacts on intimacy were more likely to 
have discussed intimacy with the HTC, but less likely to report the discussions as 
very helpful. More parents reporting NEs telling friends reported impacts on 
siblings (28% vs 18%). Haemophilia management including nurses and social 
workers was more often reported for PWH with any NE. More PWH reporting NEs 
with relationships or friends reported treatment for psychological conditions. 
Parents reporting work-related NEs reported more mean/median HTC visits per 
year (6.3/3 vs 4.1/2). Social worker involvement and treatment for psychological 
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conditions were more frequent in parents with NEs related to work or friends. 
CONCLUSIONS: PWH with one NE were more likely to report other NEs. 
PWH/parents with NEs reported greater social worker involvement and 
treatment for psychological conditions. Further studies are needed to assess 
temporal relationships between NEs and HTC visits/advice, and support the 
relevance of timely social work and psychological counselling in comprehensive 
care.  
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OBJECTIVES: Pain is not a disease, but might be a symptom of a disease, the 
effect of a disease or an accident. It pervades a person’s daily life activities, social 
interaction and productive hours. It has powerful psychological and social 
consequences. In Russia, there are no solid estimates of the magnitude of the 
condition. This study is aimed to assess co-morbidity, quality of life (QOL), 
work/productivity loss, and resource utilization in Russian urban adults with 
pain. METHODS: Patients’ self-reported data were collected from 2011 National 
Health and Wellness Survey (NHWS). Survey represented major urban areas in 
Russia. QOL was measured by the physical (PCS) and mental (MCS) component 
summary scores of the (SF-12v2). Loss of work/productivity was measured by the 
Work Productivity and Activity Impairment instrument. Medical resource 
utilization was measured by health care provider, ambulance request and 
hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 
2,670 (28%) reported to experience pain over the past month (17% mild, 54% 
moderate and 28% severe) – 35% not receiving medication at all. Average age of 
patients experiencing pain was 41.5 years. Pain group reported more co-
morbidities (headaches 77%, sleep difficulties 54%, insomnia 47%, heartburn 45%, 
depression 39%, high blood pressure 33%), lower mean scores of PCS (43.4 
vs.47.8) and MCS (40.0 vs. 45.0), more patients visited health care providers (83% 
vs. 67%), and a higher percentage were hospitalized (13% vs. 8%) over the past 6 
months compared to no experiencing pain group. Furthermore, pain group 
reported 35.9% impairment in daily activity compared to 23.0% in no 
experiencing pain group. All mentioned differences were statistically significant 
(p < 0.05) and all percentages or means are projected values. CONCLUSIONS: 
From Russian NHWS results, patients experiencing pain suffer from impairment 
in QOL, work/productivity loss and more co-morbidities. Findings indicate there 
is still an unmet medical need in Russian patients with pain.  
 
PSY89  
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OBJECTIVES: The occurrence of obesity in the UK is rapidly increasing, and is 
associated with significant health problems and economic costs. Despite this, 
there is currently only one drug recommended by NICE for the treatment of 
obesity. The purpose of the study was to examine whether the clinical 
development of obesity treatments is keeping up with the increasing obese 
population in the UK. METHODS: Adult obesity prevalence data for England were 
obtained from the 2011 Health Survey for England Trend Tables. Total economic 
costs were obtained from the National Obesity Observatory. ClinicalTrials.gov 
was searched for the number of clinical trials investigating drug and device 
interventions for obesity initiated yearly from database inception to the 17th of 
January 2013. Results were reviewed to exclude trials investigating dietary 
supplements, behavioural changes, dietary changes, and those without a UK 
centre. RESULTS: The prevalence of obese adults in England has risen from 
14.9% (1993) to 24.8% (2011). This has been associated with an estimated increase 
in total costs to the UK of £2.6 billion (1998) to £15.8 billion (2007). Since 2000, 46 
trials have been initiated investigating treatments for obesity. The number of 
clinical trials initiated yearly has increased since 2000; however recent years 
have seen a decline. 1 trial was initiated in 2000, generally increasing up until 
2010 when 8 trials were initiated. 2011 and 2012 both saw a dip in the number of 
initiated trials, with only 3 trials started in 2012. CONCLUSIONS: The prevalence 
and economic burden of obesity has increased drastically in the UK over the past 
18 years. The rate of clinical development has also increased; however, this rate 
is low in relation to the significance of this health problem and the increase in 
the obese population. These results highlight the need for further clinical 
development in treating obesity.  
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OBJECTIVES: This study aims to quantify the impact of (1) black box warning, (2) 
CMS National Coverage Determination (NCD), and (3) Risk Evaluation and 
Mitigation Strategies (REMS) on erythropoiesis-stimulating agents (ESAs) on-label 
and off-label utilization patterns among adult inpatients. METHODS: Electronic 
health records in Cerner HealthFact database from January 2005 to June 2011 
were used. Eligible patients for ESA prescribing were categorized using ICD-9-CM 
codes and medication information. The three patient categories were (1) on-label 
(ONS, conditions approved by the FDA); (2) off-label supported (OFS, strong 
clinical evidence for use in unapproved indications); and (3) off-label 
unsupported (OFU, low/no evidence supporting use in unapproved indications). 
The likelihood of receiving ESAs was assessed using a generalized estimating 
equation approach with binary logistic regression technique, clustering for 
hospitals, and controlling for potential confounders. RESULTS: We identified 
730,421 patients with ONS conditions (33,004 users, 4.5%), 505, 658 with OFS 
conditions (5,140 users, 1.0%), and 558,917 patients with OFU conditions (4,491 
users, 0.8%). Black box warning and REMS had no impact on the odds of receiving 
ESAs. There was a significant decline in all three use categories the month 
following NCD. ONS patients were 13% less likely to receive ESAs (OR 0.867, 95% 
CI 0.762, 0.986, p = 0.0299). OFS patients were 20% less likely (OR 0.799, 95% CI 
0.716, 0.891, p < 0.0001) and OFU patients were 38% less likely to receive ESAs (OR 
0.622, 95% CI 0.474, 0.817, p = 0.0006). Age, gender, race, source of payment, 
admission type, clinical complexity, discharge disposition, and hospital size were 
significantly associated with on-label and off-label use. CONCLUSIONS: We 
demonstrated the relative impact of three safety interventions on on-label and 
off-label ESA use in the hospital settings. Reimbursement change may have 
unintentionally reduced the likelihood of receiving ESAs in patients who could 
have otherwise benefited.  
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OBJECTIVES: Escalating rates of prescription opioid use and abuse have occurred 
in the context of efforts to improve the identification and management of non-
malignant pain. To characterize the diagnosis and management of non-
malignant pain in ambulatory, office-based settings between 2000 and 2010. 
METHODS: Serial cross-sectional and multivariate regression analyses of the 
National Ambulatory Medical Care Survey (NAMCS), a nationally representative 
audit of office-based physician visits. The main outcome measures were 1) 
Annual volume of visits among adults with a primary symptom or diagnosis of 
pain, and 2) prescription opioid and non-opioid pharmacologic therapy in visits 
limited to new musculoskeletal pain. RESULTS: Primary symptoms or diagnoses 
of pain consistently represented one-fifth of visits, varying less than 2% from 
2000 through 2010. Patient-reported pain comprised 17% to 19% of visits, 
whereas provider diagnoses of pain increased nearly 50% from 2000 (5.7% of 
visits with pain as a primary diagnosis) to 2010 (8.5%). Among all pain visits, 
opioid use nearly doubled from 11.3% to 19.6%, whereas use of non-opioid 
analgesics remained unchanged (26%-29% of visits). Pain medications were 
associated with one-half of new musculoskeletal pain visits, with the use of non-
opioid pharmacotherapies decreasing from 38% of visits (2000) to 29% of visits 
(2010). After adjusting for potentially confounding covariates, few patient, 
physician or practice characteristics were associated with the use of non-opioid 
rather than opioid analgesia. CONCLUSIONS: Increased opioid use during the 
past decade has not been accompanied by similar increases in non-opioid 
analgesics. Clinical alternatives to prescription opioids may be underutilized as a 
means of treating ambulatory non-malignant pain.  
 
RESEARCH POSTER PRESENTATIONS – SESSION III  
DISEASE-SPECIFIC STUDIES 
 
CANCER – Clinical Outcomes Studies 
 
PCN1  
META-ANALYSIS OF NEPHROTOXICITY IN PATIENTS WITH SOLID TUMORS 
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OBJECTIVES: Glomerular filtration rate (GFR) is known to better estimate renal 
function than serum creatinine (SCr), but SCr is commonly used when screening 
patients for inclusion into clinical trials of the nephrotoxic drug cisplatin. The 
objective of this meta-analysis was to indirectly compare incidence of 
nephrotoxicity in trials including cisplatin when renal function was assessed 
using either SCr or GFR for eligibility criteria. METHODS: A PubMed literature 
search identified randomized trials comparing cisplatin to non-cisplatin 
regimens. Included studies were performed from 1990-2010, used SCr or GFR as 
inclusion criteria, and reported incidence of WHO grade ≥3 nephrotoxic events 
for both treatment arms. Review articles, observational studies, phase 1 studies, 
non-randomized trials, studies without a comparator group, or studies not 
reported in English were excluded. Inverse variance weighted fixed effects (FE) 
and random effects (RE) methods were used to estimate the relative risk (RR) 
associated with cisplatin versus non-cisplatin regimens with sub-group analyses 
of studies using SCr, GFR, and either SCr or GFR for screening. RESULTS: A total 
of 2,359 studies were identified from the literature search and 29 studies met all 
inclusion and exclusion criteria (N=6,146 patients). Of these, 18 studies used SCr 
(N=4,146), 5 used GFR (N=993), and 6 used SCr or GFR (N=1,007) for screening. The 
overall RR for developing nephrotoxicity with cisplatin versus non-cisplatin 
treatment was 2.09 (95%CI 1.33-3.27, p=0.001). In sub-group analyses, the RR was 
2.47 (95%CI 1.24-4.94, p=0.011) for SCr, 1.84 (95%CI 0.96-3.54, p=0.067) for GFR, and 
1.88 (95%CI 0.49-7.26, p=0.359) for either SCr or GFR. Results did not vary between 
